Deciphera Pharmaceuticals, a clinical-stage developer of kinase-inhibiting cancer drugs, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Waltham, MA-based company was founded in 2003 and plans to list on the Nasdaq under the symbol DCPH. Deciphera Pharmaceuticals filed confidentially on June 23, 2017. J.P. Morgan and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
